Anti-Alpha Synuclein Antibody (FITC)
Rabbit polyclonal antibody to Alpha Synuclein (FITC) from FabGennix (NACP-FITC).
|Name:||Anti-Alpha Synuclein Antibody (FITC)|
|Description:||Rabbit polyclonal antibody to Alpha Synuclein (FITC)|
|Applications:||ELISA, IHC, IP, WB|
|Dilutions:||DB: 1:20,000; ELISA: 1:20,000; Western Blot: 1:500|
|Immunogen:||Synthetic peptide taken within amino acid region 62-112 unique sequence on alpha-synuclein isoform NACP 112 protein.|
|Concentration:||0.68-0.70 µg/µl in antibody stabilization buffer|
|Storage:||-20⁰C for long term storage|
|Function:||May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.|
|Tissue Specificity:||Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.|
|Involvement in Disease:||Parkinson disease 1, autosomal dominant: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.
Parkinson disease 4, autosomal dominant: A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.
Dementia Lewy body: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.
|Sequence Similarities:||Belongs to the synuclein family.|
|Post-Translational Modification:||Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.|
|Cellular Location:||Cytoplasm > Cytosol. Membrane. Nucleus. Cell junction > Synapse. Secreted.
Membrane-bound in dopaminergic neurons.
Alpha-synuclein, isoform NACP140 Antibody
Non A beta component of AD amyloid Antibody
Non A4 component of amyloid Antibody
Non A4 component of amyloid precursor Antibody
Non-A beta component of AD amyloid Antibody
Non-A-beta component of alzheimers disease amyloid , precursor of Antibody
Non-A4 component of amyloid precursor Antibody
Non-A4 component of amyloid, precursor of Antibody
PARK 1 Antibody
PARK 4 Antibody
Parkinson disease (autosomal dominant, Lewy body) 4 Antibody
Parkinson disease familial 1 Antibody
PD 1 Antibody
Snca synuclein, alpha (non A4 component of amyloid precursor) Antibody
Synuclein alpha Antibody
Synuclein alpha 140 Antibody
Synuclein, alpha (non A4 component of amyloid precursor) Antibody
|Information:||Target information shown above is from the UniProt Consortium.|
Please Note: Anti-Alpha Synuclein Antibody (FITC) is for research use only. It is not intended for diagnostic of therapeutic use.